Drug Trial Radar · NCT07220616
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
Last checked: Nov 19, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
420
Planned (sponsor's estimate)
Start
Jan 16, 2026
Primary completion
Nov 30, 2030
Study completion Nov 30, 2030
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- First posted
- Oct 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is designed to assess the safety, preliminary efficacy, and pharmacokinetics (PK) of DS3790a monotherapy and combination regimens in participants with hematological malignancies.
Conditions
- Hematological Malignancies
- B-cell Non-Hodgkin Lymphoma
Interventions
DS3790aDrug
Administered as specified in the protocol
Combination drugDrug
Administered as specified in the protocol
Combination drugDrug
Administered as specified in the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Reporting Dose-limiting Toxicities, Treatment-emergent Adverse Events, Serious Adverse Events, Adverse Events of Special Interest, and Deaths in Participants With Hematological MalignanciesTime frame: Baseline up to 5 years
- Complete Response in Participants With Hematological Malignancies by Blinded Independent Central Review (Cohort A Randomization Optimization Phase, Cohort A Phase 2)Time frame: Baseline up to 5 years
- Complete Response in Participants With Hematological Malignancies by Investigator Assessment (Cohort B Randomization Optimization Phase)Time frame: Baseline up to 5 years
Locations
8 sites in 4 countries. Site status is shown where the registry gives one.
Research Site
New York, New York · Recruiting
Research Site
Lille, France · Recruiting
Research Site
Pierre-Bénite, France · Recruiting
Research Site
Villejuif, France · Recruiting
Research Site
Bologna, Italy · Recruiting
Research Site
Nagoya, Japan · Recruiting
Research Site
Tokyo, Japan · Recruiting
Research Site
Tokyo, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.